Abstract: Carvacrol is a monoterpene found in essential oils from various plants. Several 9 pharmacological properties have already been described for carvacrol, including antimicrobial,
Introduction

29
Normal erectile function depends on a precise balance between relaxation and 30 contraction of the cavernous smooth muscle, which is regulated by neural and local control 31 mechanisms. Therefore, changes in these mechanisms may lead to erectile dysfunction (ED) 32 [1] . This clinical condition has been defined by the United States National Institutes of Health 33 as the inability to achieve or maintain a penile erection that would enable satisfactory sexual 34 activity [2] . 35 ED is closely associated with chronic diseases, such as diabetes and systemic arterial 36 hypertension [3] . Several studies have reported a greater prevalence of ED in hypertensive 37 patients compared to normotensive individuals [4] [5] [6] . In addition, studies have identified ED 38 as a predictive factor for the development of hypertension [7] . In both situations, ED is 39 triggered by deregulation of endothelial factors and increased smooth muscle contraction, 40 which consequently causes an increase in vascular pressure, poor cavernous perfusion and 41 inadequate intumescence [8] . 42 ED treatment is based on the use of PDE-5 inhibitors, such as sildenafil, vardenafil and 43 tadalafil. However, in recent years, the number of studies seeking to develop new strategies 44 for the treatment of ED has been increasing [9] since treatment with PDE-5 inhibitors is less 45 effective in patients with an impaired nitric oxide (NO) pathway, especially individuals with 46 vascular diseases [10] . Antioxidant compounds have been gaining prominence in these 47 studies as they reduce oxidative damage, improve NO bioavailability and have a protective 48 effect on erectile function [11] [12] [13] . 49 Carvacrol is an aromatic monoterpene found in essential oils from various plants, such as 50
Origanum vulgarem (oregano), Thymus vulgaris (thyme) and Citrus aurantium bergamia 51 (bergamot) [14] , and has been shown to have potent antioxidant activity [15, 16] Some studies highlight antioxidant activity induced by carvacrol, with the compound 55
improving not only the activity of antioxidant enzymes but also the activity of non-enzymatic 56
antioxidants [14] . In addition, carvacrol plays a role in the cardiovascular system, acting as a 57
vasodilator through the interaction with voltage-gated calcium (CaV) and transient receptor 58 potential (TRP) channels, which also contribute to a hypotensive effect [22, 23] . Based on the 59 range of pharmacological activities already described for carvacrol and especially its 60 antioxidant activity, this study aimed to evaluate the effect of carvacrol on the erectile 61 dysfunction of SHR. 62 63 
Results
64
Carvacrol induces antihypertensive effect in SHR
71
SHR-CTL (n = 5; ■); SHR-C50 (n = 6; Δ); SHR-C100 (n = 6;▼); SHR-S1.5 (n = 6; ◊). Results are 72 expressed as mean ± SEM. Data were analyzed using two-way ANOVA, followed by Bonferroni 
Carvacrol improve the ICP/MAP ratio in SHR
75
The ICP/MAP ratio was significantly lower in the SHR-CTL group (1Hz = 0.09 ± 0.02; 2Hz = 0.12 76 ± 0.02; 4Hz = 0.15 ± 0.02; 8Hz = 0.18 ± 0.02; 12Hz = 0.18 ± 0.02; n = 5) when compared to that in the 
79
The SHR-C100 treatment (2Hz = 0.27 ± 0.03; 4Hz = 0.32 ± 0.04; 8Hz = 0.36 ± 0.04; 12Hz = 0.34 ± 80 0.04; n = 5) improved the ICP/MAP ratio of hypertensive animals (SHR-CTL) (Figure 2a, b) .
81
Interestingly, the response induced in the SHR-C100 group did not present a significant difference 
89
SHR-CTL (n = 5; ■); SHR-C50 (n = 5; Δ); SHR-C100 (n = 5; ); SHR-S1.5 (n = 6; ◊). Results are
90
expressed as mean ± SEM. Data were analyzed using two-way ANOVA, followed by Bonferroni 91 post-test. *p < 0.05 vs WKY-CTL; # p < 0.05 vs SHR-CTL.
92
Carvacrol improves relaxation of the corpora cavernosa when exposed to ACh and SNP in SHR 93
ACh (0.1 nM -100 μM) induced significantly lower relaxation in the corpora cavernosa of the 94 SHR-CTL group (Emax = 16.5 ± 3.8%, n = 6) when compared to that in the corpora cavernosa of the 95 WKY-CTL group (Emax = 36.7 ± 6.7%, n = 5, p < 0.05) (Figure 3a ).
96
The SHR-C100 treatment (Figure 3a ) improved the ACh-induced relaxation response (Emax =
97
38.0 ± 6.4%, n = 5, p < 0.05) in hypertensive rats, and this response was similar to the response 98 observed in the WKY-CTL and SHR-S1.5 groups (Emax = 28.6 ± 3.9%, n = 5) ( Figure 3a) . However, the
99
SHRC50 group (Emax = 20.4 ± 3.3%, n = 5) did not exhibit an altered ACh-induced relaxation response
100
( Figure 3a ).
102
Figure 3 -Vascular reactivity to ACh (a) and SNP (b) in rat corpora cavernosa. Groups: WKY-CTL (n 103 = 5; •); SHR-CTL (n = 6; ■); SHR-C50 (n = 5; Δ); SHRC100 (n = 5; ); SHR -S1.5 (n = 5; ◊). 
106
SNP (10 nM -300 μM) induced significantly lower relaxation in the corpora cavernosa of the 107 SHR-CTL group (Emax = 72.2 ± 4.1%; n = 5) when compared to that in the corpora cavernosa of the
108
WKY-CTL group (Emax = 100.8 ± 5.0%; n = 7; p < 0.05) (Figure 3b ). In the SHR-C50 (Emax = 89.6 ± 3.9%; n 109 = 7), SHR-C100 (Emax = 90.9 ± 2.0; n = 6) and SHR-S1.5 (92.9 ± 8.1, n = 7) groups, the SNP-induced 110 relaxation response in the corpora cavernosa was restored (p < 0.05) (Figure 3b ).
111
Carvacrol reduces hypercontractility of the corpora cavernosa in SHR
112
Phe (10 nM -300 μM) induced significantly greater contraction in the corpora cavernosa of the 113 SHR-CTL group (pD2 = 5.4 ± 0.1; Emax = 146.7 ± 6.0%; n = 5) when compared to that in the corpora 114 cavernosa of the WKY-CTL group (pD2 = 5.0 ± 0.05; Emax = 104.7 ± 8.5%; n = 5) ( Figure 4a ).
115
In the SHR-C50 (Emax = 102.8 ± 12.0%; n = 6; p < 0.05) ( Figure 4a ) and SHR-C100 (Emax = 78.0 ± 116 10.6; n = 5; p < 0.05) (Figure 4a ) groups, the hypercontractility response to Phe that was observed in 117 the SHR-CTL group was reduced (p < 0.05). On the other hand, the SHR-S1.5 group (pD2 = 5.2 ± 0.2; 
124
SHR-CTL (n = 5; ■); SHR-C50 (n = 6; Δ); SHR-C100 (n = 5; ); SHR-S1.5 (n = 6; ◊). Results are
125
expressed as mean ± SEM. Data were analyzed using two-way ANOVA, followed by Bonferroni 146.7 ± 6.0%; n = 5) in the absence of tempol ( Figure 5a ).
138
Interestingly, tempol did not modify the contractile response to Phe in the SHR-50-TEMPOL
139
(Emax = 93.3 ± 10.2%; n = 5) ( Figure 5b ) and SHR-C100-TEMPOL (Emax = 66.7 ± 13.6%; n = 5) ( Figure 5c )
140
groups when compared to that in the groups without tempol, SHR-C50 and SHR-100.
141
On the other hand, with the addition of tempol, the contractile response induced by Phe was 142 reduced in the corpora cavernosa of the SHR-S1.5-TEMPOL (Emax = 98.0 ± 6.5%; n = 5) mice when 5; □); SHR-C50 (n= 6; Δ); SHR-C50-TEMPOL (n= 4; ▲); SHR-C100 (n = 5; ▼); SHR-C100-TEMPOL (n 149 = 6; ); SHR-S1.5 (n = 6; ◊); SHR-S1.5-TEMPOL (n = 5; ♦). Results are expressed as mean ± SEM.
Data were analyzed using the two-way ANOVA, followed by Bonferroni post-test. *p < 0.05 vs
151
WKY-CTL; # p < 0.05 vs SHR-CTL.
152
Carvacrol reduces reactive oxygen species in the corpus cavernosum of SHR
153
The DHE probe emitted baseline fluorescence in the rat corpora cavernosa sections of all 
157
The corpora cavernosa sections of the SHR-C50 (101.3 ± 10.1%; n = 5), SHR-C100 (103.4 ± 5.0%; n
158
= 6) and SHR-S1.5 (142.5 ± 6.1%; n = 6) groups showed a significant reduction in the fluorescence 159 intensity emitted by the DHE probe when compared to that emitted by the DHE probe in the The use of plant products has been an important alternative and has been the subject of several 179 studies demonstrating their potential in the treatment of ED [11, 13, 25] 
196
Interestingly, carvacrol or sildenafil treatments were able to reduce SBP to, virtually, the same level.
197
Erectile function was assessed by the ICP/MAP ratio. function in rat corpora cavernosa [11, 35] .
226
In addition to endothelial dysfunction, hypertension may cause impairment of pathways 227 directly involved in the relaxation of smooth muscle cells of the penile tissue [7] . Therefore, SNP, a
228
NO donor, was used to assess endothelium-independent relaxation. In response to SNP, a reduction 229 of the maximum effect on the SHR-CTL group was observed when compared to the WKY-CTL the Phe-induced contraction in the corpora cavernosa of SHR -CTL rats.
275
The pre-incubation with tempol in SHR-C50 and SHR-C100 rats had no additive effect in 276 reducing Phe-induced contraction when compared to the effect in the absence of this scavenger. We
277
suggest that treatment with carvacrol at both doses probably reduces contractility through a 278 mechanism similar to that induced by tempol. Conversely, pre-incubation with tempol in the 279 SHR-S1.5 group reduced the Phe-mediated contractile response when compared to the SHR-CTL 280 group, suggesting that treatment with sildenafil seems to improve erectile function mainly by other 281 mechanisms.
To confirm the modulating effect of oxidative stress, we evaluated whether treatment with
283
carvacrol was able to modify baseline ROS levels in corpus cavernosum sections of SHR by 284 measuring the DHE fluorescence intensity.
285
In these experiments, the SHR-CTL group showed a significant increase in the DHE 
290
Treatment with carvacrol in the two doses studied (50 and 100 mg/kg) significantly reduced
291
DHE fluorescence levels when compared to those of the SHR-CTL group, presenting superoxide 292 anion levels similar to those of the WKY-SHR group. Animals from the SHR-S1.5 group also showed 293 a reduction in the DHE fluorescence intensity; however, this response was not reversed to the 294 baseline levels of the WKY-CTL group. This result suggests that treatment with sildenafil reduces 295 oxidative stress; however, this does not appear to be the main mechanism by which erectile function 296 is improved.
297
As previously mentioned, the increase in superoxide anion production in 
301
Finally, TRPC3 and TRPC4 channels are involved in the positive modulation of oxidative stress.
302
The TRPC3 channel amplifies ROS formation through an interaction with NADPH oxidase (Nox2),
303
which causes the stabilization of this protein complex and consequently increases ROS production, 
Study design
318
The rats were randomly divided into five experimental groups: normotensive control
319
(WKY-CTL; n = 8); hypertensive control (SHR-CTL; n = 8); hypertensive rats treated with 50 320 mg/kg/day carvacrol (SHR-C50; n = 8) or 100 mg/kg/day carvacrol (SHR-C100; n = 8); and 321 hypertensive rats treated with 1.5 mg/kg/day sildenafil (SHR-S1.5, n = 8). All animals received their 322 treatments intragastrically for four weeks. 
336
The systolic blood pressure (SBP) of the rats was measured weekly using the tail-cuff method
337
(Panlab, Harvard Apparatus, Spain). To measure the blood pressure, the rats were kept in a heated 338 acrylic container (28-30ºC) for 10 minutes prior to the measurement to make the caudal artery 
360
Strips of corpus cavernosum were suspended by metal rods connected to a force transducer and 361 inserted into tanks for isolated organ baths (Panlab Multi Chamber Organ Baths, ADInstruments) 362 containing 10 mL of solution at 37°C that was continuously bubbled with a mixture of 95% O2 and 363 5% CO2 (pH 7.4). The strips were maintained under a basal tension of 0.5 g for a stabilization period 364 of 60 minutes. The tension changes were measured using isometric transducers (MLT020,
365
ADInstruments, Australia) and recorded in the PowerLab® system (ML870/P, LabChart version 7.0,
366
ADInstruments, Australia).
367
The contractility of the rat corpora cavernosa was evaluated by increasing the cumulative 368 concentration of Phe (10 nM -300 μM) and via electrical field stimulation (EFS). The EFS was 369 performed using 50 V electric pulses having a duration of 1 ms at different frequencies (1, 2, 4, 8 and
370
16 Hz) with a duration of 10 seconds for each frequency. The contractile response of the corpora 371 cavernosa to Phe was also evaluated by pre-incubation for 30 minutes with tempol (1 mM), which is 
374
-100 μM), which is an endothelial muscarinic agonist, or to SNP (10 nM -300 μM), which is an 375 spontaneous NO donor. 
